Prevention and treatment of respiratory syncytial virus disease among children: study design optimization workshop, meeting report, 9, 24 and 25 June and 7 October 2026
Overview
Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness and mortality among young children, particularly in low- and middle-income countries. Following the WHO-led paediatric drug optimization (PADO) process for RSV, WHO convened a series of technical consultations between June and October 2026 to align approaches to evidence generation for RSV prevention and treatment in children. The consultations examined regulatory requirements, clinical trial designs and key endpoints for novel RSV monoclonal antibodies and antiviral agents in an evolving prevention landscape.
The report identifies priorities for efficient, pragmatic trials, including clinically meaningful endpoints, appropriate comparators, and the use of evidence extrapolation and pharmacokinetic and safety bridging to streamline regulatory pathways. For antiviral trials, particular emphasis is placed on disease progression outcomes, early treatment and standardized core outcome measures. Participants highlighted the importance of regulatory alignment, ethically appropriate study designs and greater inclusion of low- and middle-income countries. Integrating equitable access and implementation considerations into product development is emphasized to support regulatory decisions, policy recommendations and wider availability of RSV prevention and treatment.